Morgan Stanley’s Organogenesis Holdings ORGO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.5M | Sell |
11,616,795
-22,041
| -0.2% | -$76.4K | ﹤0.01% | 2650 |
|
|
2025
Q4 | $60.3M | Sell |
11,638,836
-157,889
| -1% | -$765K | ﹤0.01% | 1909 |
|
|
2025
Q3 | $49.8M | Sell |
11,796,725
-259,222
| -2% | -$1.21M | ﹤0.01% | 2009 |
|
|
2025
Q2 | $44.1M | Sell |
12,055,947
-60,028
| -0.5% | -$224K | ﹤0.01% | 2045 |
|
|
2025
Q1 | $52.3M | Buy |
12,115,975
+285,398
| +2% | +$1.15M | ﹤0.01% | 1777 |
|
|
2024
Q4 | $37.9M | Sell |
11,830,577
-139,157
| -1% | -$467K | ﹤0.01% | 2094 |
|
|
2024
Q3 | $34.2M | Buy |
11,969,734
+393,675
| +3% | +$1.1M | ﹤0.01% | 2229 |
|
|
2024
Q2 | $32.4M | Buy |
11,576,059
+48,031
| +0.4% | +$129K | ﹤0.01% | 2158 |
|
|
2024
Q1 | $32.7M | Sell |
11,528,028
-15,227,484
| -57% | -$51.7M | ﹤0.01% | 2167 |
|
|
2023
Q4 | $109M | Buy |
26,755,512
+19,814,968
| +285% | +$55.5M | ﹤0.01% | 1637 |
|
|
2023
Q3 | $22.1M | Buy |
6,940,544
+5,994,373
| +634% | +$19M | ﹤0.01% | 2346 |
|
|
2023
Q2 | $3.14M | Buy |
946,171
+422,152
| +81% | +$1.25M | ﹤0.01% | 4111 |
|
|
2023
Q1 | $1.12M | Sell |
524,019
-1,455,098
| -74% | -$3.59M | ﹤0.01% | 4797 |
|
|
2022
Q4 | $5.32M | Sell |
1,979,117
-1,272,952
| -39% | -$3.71M | ﹤0.01% | 3707 |
|
|
2022
Q3 | $10.5M | Sell |
3,252,069
-262,413
| -7% | -$1.19M | ﹤0.01% | 2913 |
|
|
2022
Q2 | $17.2M | Buy |
3,514,482
+515,655
| +17% | +$3.17M | ﹤0.01% | 2453 |
|
|
2022
Q1 | $22.9M | Buy |
2,998,827
+1,333,720
| +80% | +$10.3M | ﹤0.01% | 1973 |
|
|
2021
Q4 | $15.4M | Buy |
1,665,107
+238,330
| +17% | +$2.53M | ﹤0.01% | 2455 |
|
|
2021
Q3 | $20.3M | Sell |
1,426,777
-422,819
| -23% | -$6.57M | ﹤0.01% | 2069 |
|
|
2021
Q2 | $30.7M | Buy |
1,849,596
+1,770,888
| +2,250% | +$33M | ﹤0.01% | 1717 |
|
|
2021
Q1 | $1.43M | Sell |
78,708
-380,307
| -83% | -$5.15M | ﹤0.01% | 4499 |
|
|
2020
Q4 | $3.46M | Buy |
459,015
+445,415
| +3,275% | +$2.12M | ﹤0.01% | 3664 |
|
|
2020
Q3 | $52K | Sell |
13,600
-6,390
| -32% | -$25.2K | ﹤0.01% | 5713 |
|
|
2020
Q2 | $77K | Buy |
19,990
+1,529
| +8% | +$5.51K | ﹤0.01% | 5519 |
|
|
2020
Q1 | $60K | Buy |
18,461
+3,473
| +23% | +$14.9K | ﹤0.01% | 5397 |
|
|
2019
Q4 | $72K | Buy |
14,988
+10,930
| +269% | +$69.3K | ﹤0.01% | 5758 |
|
|
2019
Q3 | $27K | Buy |
4,058
+3,734
| +1,152% | +$20.8K | ﹤0.01% | 5928 |
|
|
2019
Q2 | $2K | Sell |
324
-3,735
| -92% | -$27.5K | ﹤0.01% | 6463 |
|
|
2019
Q1 | $30K | Buy |
+4,059
| New | +$81.1K | ﹤0.01% | 5880 |
|
|
2018
Q4 | – | Sell |
-2
| Closed | – | – | 6683 |
|
|
2018
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 6770 |
|
|
2018
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 6722 |
|
|
2018
Q1 | $0 | Sell |
2
-200
| -99% | -$1.99K | ﹤0.01% | 6668 |
|
|
2017
Q4 | $2K | Buy |
+202
| New | +$2.01K | ﹤0.01% | 6449 |
|
Other funds holding ORGO
SCM
FLAM
VCM
Morgan Stanley's ORGO Position: Q1 2026 in Review
Morgan Stanley reduced its Organogenesis Holdings (ORGO) stake by 0.19% in Q1 2026, selling an estimated $76.4K and leaving 11,616,795 shares worth $27.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2650.
Morgan Stanley first reported a position in ORGO in Q4 2017 and has held it in 33 quarters since. The position peaked at $109M in Q4 2023. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.
- Morgan Stanley held 11,616,795 shares of Organogenesis Holdings worth $27.5M as of Q1 2026.
- Morgan Stanley sold 22,041 Organogenesis Holdings shares in Q1 2026, an estimated $76.4K.
- Organogenesis Holdings made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2650 holding.
- Morgan Stanley first reported a position in Organogenesis Holdings in Q4 2017 and has held it in 33 quarters since.
- Morgan Stanley's Organogenesis Holdings position peaked at $109M in Q4 2023.
- 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.